NCT00448604

Brief Summary

The objectives of the study are

  • to determine the prevalence of respiratory virus infections in COPD patients, during and outside acute exacerbation
  • to explore the impact of these viral infections on the outcome of these patients
  • to explore the association between blood procalcitonin levels and viral infections in this population.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
86

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2007

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 19, 2007

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2007

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2009

Completed
Last Updated

November 4, 2010

Status Verified

February 1, 2009

Enrollment Period

2.3 years

First QC Date

March 16, 2007

Last Update Submit

November 3, 2010

Conditions

Keywords

procalcitoninacute exacerbationRT-PCRBiological Markers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with COPD admitted with acute exacerbation

You may qualify if:

  • All consecutive patients known or suspected for moderate to very severe COPD and admitted in the emergency center for an acute exacerbation of their COPD
  • Age above 18 years
  • We plan to include 100 patients with a complete work-up and follow-up
  • Written informed consent will be obtained from every participant

You may not qualify if:

  • Patients requiring oro-tracheal intubation
  • Patients unable to give their informed consent due to their clinical condition
  • Other obvious cause of dyspnea (pulmonary embolism, acute pulmonary edema, lobar pneumonia)
  • Patients suffering from bronchiectasis, asthma, pulmonary fibrosis and mineral dust pneumoconiosis
  • Patients with a history of active tuberculosis
  • Patients with a history of ischemic cerebral stroke and subsequent deglutition dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Geneva University Hospital

Geneva, Canton of Geneva, 1211, Switzerland

Location

Related Publications (1)

  • Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, Rutschmann OT. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010 Oct;138(4):896-904. doi: 10.1378/chest.09-2225. Epub 2010 Apr 30.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Naso-pharyngeal swaps

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveRespiratory Tract InfectionsVirus DiseasesLung Diseases, Obstructive

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsInfections

Study Officials

  • Olivier T Rutschmann, MD, MPH

    University Hospital, Geneva

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 16, 2007

First Posted

March 19, 2007

Study Start

May 1, 2007

Primary Completion

September 1, 2009

Study Completion

September 1, 2009

Last Updated

November 4, 2010

Record last verified: 2009-02

Locations